For patients with neovascular age-related macular degeneration (nAMD), ranibizumab with a port delivery system (PDS) with one refill costs more than intravitreal ranibizumab or aflibercept injections if about 11 or 10 injections, ...
Jun 23, 2022
0
2
A computer modeling study suggests that administering the drug ranibizumab is associated with reducing the magnitude of legal blindness and visual impairment caused by age-related macular degeneration in non-Hispanic white ...
Jun 13, 2011
0
0
Two major drug trials conclude there was little risk from a drug aimed at age-related macular degeneration. Yet a Mayo Clinic ophthalmologist began to note something concerning in some of her patients: an increase in pressure ...
Oct 24, 2011
0
1
People who are losing their eyesight through aged-related macular degeneration (AMD) may soon be able to find out if a commonly used drug can help save their vision.
Mar 15, 2012
0
0
At two years, Avastin (bevacizumab) and Lucentis (ranibizumab injection), two widely used drugs to treat age-related macular degeneration (AMD), improve vision when administered monthly or on an as needed basis, although ...
Apr 30, 2012
1
0
Millions of people with "wet" macular degeneration are prescribed a class of medication known as anti-VEGF drugs. But now scientists at The Scripps Research Institute (TSRI) have found that a drastic reduction of VEGF activity ...
Oct 25, 2012
0
0
Health policies which favour using ranibizumab for treating eye disease in older people over safety concerns for a cheaper alternative should take account of a new Cochrane Review published today. The researchers looked at ...
Sep 14, 2014
0
0
(HealthDay)—For patients with vitreous hemorrhage from proliferative diabetic retinopathy (PDR), the probability of vitrectomy within 16 weeks after intravitreal injections of ranibizumab or saline is lower than expected, ...
Feb 1, 2013
0
0
(HealthDay)—For patients with diabetic macular edema, repeated ranibizumab treatment does not appear to be associated with impaired macular perfusion, according to a study published online March 1 in JAMA Ophthalmology.
Mar 7, 2018
0
12
(HealthDay)—Long-term aggressive treatment of patients with macular edema with ranibizumab during a third year correlates with reduced mean foveal thickness (FTH) and improved best-corrected visual acuity (BCVA), according ...
Oct 11, 2012
0
0
